ERBB2 and breast carcinoma: Schettini et al. used a novel methodology to detect surface antigen to develop ADC and CAR-T against breast cancer already and identified PTPRT as a novel potential target for molecular Luminal A or immunohistochemical HR+/HER2-negative BC [13].